Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis

N Engl J Med. 2019 Jun 13;380(24):2377-2379. doi: 10.1056/NEJMc1901677.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Abatacept / therapeutic use*
  • Aged
  • Antineoplastic Agents, Immunological / adverse effects*
  • Female
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Lung Neoplasms / drug therapy
  • Myocarditis / chemically induced
  • Myocarditis / drug therapy*
  • Myositis / chemically induced
  • Nivolumab / adverse effects*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*

Substances

  • Antineoplastic Agents, Immunological
  • Immunosuppressive Agents
  • Programmed Cell Death 1 Receptor
  • Nivolumab
  • Abatacept